F L Luan

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients
    Fu L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Transplantation 91:237-44. 2011
  2. doi request reprint New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression
    Fu L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0364, USA
    Transplantation 91:334-41. 2011
  3. doi request reprint The time interval between kidney and pancreas transplantation and the clinical outcomes of pancreas after kidney transplantation
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI 48109 0364, USA
    Clin Transplant 26:403-10. 2012
  4. doi request reprint Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?
    Fu L Luan
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 0364, USA
    Kidney Int 76:825-30. 2009
  5. doi request reprint Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA
    Semin Dial 23:198-205. 2010
  6. doi request reprint Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation
    Fu L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Transplantation 89:1034-9. 2010
  7. doi request reprint Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan Taubman Center, East Medical Center Drive, Ann Arbor, MI, USA
    Clin Transplant 24:778-83. 2010
  8. pmc Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA
    J Am Soc Nephrol 20:2449-58. 2009
  9. doi request reprint Influence of recipient race on the outcome of simultaneous pancreas and kidney transplantation
    F L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Am J Transplant 10:2074-81. 2010
  10. doi request reprint A pilot study of gene expression-based categorization of pancreas transplant biopsies
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA corrected
    Transplantation 87:222-6. 2009

Detail Information

Publications23

  1. doi request reprint Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients
    Fu L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Transplantation 91:237-44. 2011
    ..We performed cost effectiveness and cost utility modeling comparing these two approaches...
  2. doi request reprint New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression
    Fu L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0364, USA
    Transplantation 91:334-41. 2011
    ..New-onset diabetes after transplant (NODAT) is a serious complication after kidney transplantation. We studied the relationship between steroid-free maintenance regimens and NODAT in a national cohort of adult kidney transplant patients...
  3. doi request reprint The time interval between kidney and pancreas transplantation and the clinical outcomes of pancreas after kidney transplantation
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI 48109 0364, USA
    Clin Transplant 26:403-10. 2012
    ..Shortening the time interval between pancreas and kidney transplantation to less than three yr may reduce the risk of kidney graft loss in qualified PAK transplant candidates...
  4. doi request reprint Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?
    Fu L Luan
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 0364, USA
    Kidney Int 76:825-30. 2009
    ....
  5. doi request reprint Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA
    Semin Dial 23:198-205. 2010
    ..Finally, re-transplantation should be recommended in suitable kidney transplant patients when the kidney allograft demonstrates continuous and progressive decline in function...
  6. doi request reprint Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation
    Fu L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Transplantation 89:1034-9. 2010
    ..We prospectively studied the relationship between AGM and MS in non-diabetic kidney transplant recipients early after transplantation...
  7. doi request reprint Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan Taubman Center, East Medical Center Drive, Ann Arbor, MI, USA
    Clin Transplant 24:778-83. 2010
    ..Metabolic syndrome (MS) and new onset diabetes after transplant (NODAT) are common in kidney transplant patients. We studied the relationship between the two conditions and their impact on metabolic and cardiovascular risk profiles...
  8. pmc Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA
    J Am Soc Nephrol 20:2449-58. 2009
    ..In summary, 6-mo prophylaxis with valganciclovir combined with a one-time determination of viremia is cost effective in reducing CMV infection and disease in seronegative recipients of seropositive kidney and/or pancreas transplants...
  9. doi request reprint Influence of recipient race on the outcome of simultaneous pancreas and kidney transplantation
    F L Luan
    Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Am J Transplant 10:2074-81. 2010
    ..42, 95% CI 1.15, 1.75, p = 0.001). In the era of modern immunosuppression, AA SPK transplant patients continue to have inferior graft outcome. Additional studies to explore the mechanisms of such racial disparity are warranted...
  10. doi request reprint A pilot study of gene expression-based categorization of pancreas transplant biopsies
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA corrected
    Transplantation 87:222-6. 2009
    ..Three of those four pancreas transplants were subsequently lost. Our study demonstrates the potential association of gene expression with clinical outcome of pancreas transplants and justifies further studies in an independent cohort...
  11. pmc Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression
    F L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA
    Am J Transplant 9:160-8. 2009
    ..De novo steroid-free immunosuppression as currently practiced in the United States appears to carry no increased risk of adverse clinical outcomes in the intermediate term...
  12. doi request reprint Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period
    F L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA
    Am J Transplant 8:1871-7. 2008
    ..4% in group I and group II, respectively (p = 0.90). In conclusion, conversion to Tac, compared to continuous exposure to CsA, carries quantitatively similar risk of impaired glucose metabolism in KTRs in the late posttransplant period...
  13. doi request reprint Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C
    Fu L Luan
    Division of Nephrology, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA
    Transplantation 85:1601-6. 2008
    ..HCV-positive kidney transplant recipients have worse clinical outcomes than those who are HCV negative. The optimal immunosuppressive regimen in this group of patients remains uncertain...
  14. ncbi request reprint Impact of simultaneous pancreas and kidney transplantation on cardiovascular risk factors in patients with type 1 diabetes mellitus
    Fu L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Transplantation 84:541-4. 2007
    ..We conclude that SPK significantly improves blood pressure and dyslipidemia compared with KTA in type 1 diabetic ESRD patients...
  15. ncbi request reprint Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients
    F L Luan
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Transplant Proc 38:3673-5. 2006
    ..Valganciclovir allowed for early initiation of treatment and for treatment to be given as an outpatient. These advantages of valganciclovir have both health and economic impact for patients with CMV disease...
  16. doi request reprint Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis
    F L Luan
    Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA
    Am J Transplant 11:1936-42. 2011
    ..15-7.61, p = 0.025). In conclusion, late-onset CMV disease continues to negatively impact kidney transplant outcome despite 6-month low-dose VGCV prophylaxis. Investigations focusing on novel preventive approaches should be emphasized...
  17. doi request reprint Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients
    F L Luan
    Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA
    Transpl Infect Dis 12:473-9. 2010
    ..We investigated the impact of various antibody induction regimens on CMV infection in this group of patients...
  18. doi request reprint Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction
    F L Luan
    Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan48109 5364, USA
    Transplant Proc 45:175-7. 2013
    ..We studied the effectiveness of 6 months of low-dose valganciclovir prophylaxis in CMV-naive kidney transplant recipients of CMV-positive donor kidney (D+/R-) receiving thymoglobulin induction...
  19. ncbi request reprint Management of hypertension in solid-organ transplantation
    Jeong M Park
    University of Michigan, Ann Arbor, MI, USA
    Prog Transplant 15:17-22. 2005
    ..The choice of an antihypertensive regimen should be tailored on the basis of the individual patient's risk factors and comorbidities...
  20. ncbi request reprint Rapamycin is an effective inhibitor of human renal cancer metastasis
    Fu L Luan
    Department of Medicine, Weill Medical College of Cornell University, New York Presbyterian Hospital New York, New York, USA
    Kidney Int 63:917-26. 2003
    ..Rapamycin is an effective inhibitor of human renal cancer metastasis...
  21. ncbi request reprint Kidney transplantation from donors without a heartbeat
    Fu L Luan
    N Engl J Med 347:1799-801; author reply 1799-801. 2002
  22. ncbi request reprint Intensive glucose control in type 2 diabetes
    Fu L Luan
    N Engl J Med 359:1519-20; author reply 1520-1. 2008
  23. ncbi request reprint Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy
    Fu L Luan
    Department of Transplantation Medicine, New York Presbyterian Hospital, New York, NY 10021, USA
    Transplantation 73:1565-72. 2002
    ..In this study, we investigated the effect of rapamycin on tumor progression, in the presence and absence of cyclosporine...